The Dyne Therapeutics (DYN) stock price has jumped more than 8% premarket after it announced positive clinical data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD).
Specifically, at the time of writing, DYN's stock is trading at $30.09, up 8.7%, adding to its well over 100% gains so far this year.
The company said new data from both trials demonstrated a "compelling impact on key disease biomarkers as well as improvement in multiple functional endpoints and favorable safety profiles."
"We believe these data reflect the best-in-class potential for these product candidates and reinforce the opportunity to transform the treatment of DM1 and DMD as well as the potential of the FORCE platform to address other rare muscle diseases,” said John Cox, Dyne’s president and chief executive officer.
Wildon Farwell, Dyne’s chief medical officer, said the company's robust preclinical work is translating into clinical benefit along with favorable safety profiles for both DYNE-101 and DYNE-251.
"In ACHIEVE, treatment with DYNE-101 demonstrated consistent, dose-dependent splicing correction, which led to an improvement in muscle strength, function, and patient reported outcomes," explained Farwell. "In DELIVER, treatment with DYNE-251 resulted in dystrophin expression that exceeded levels that have been reported for the standard of care for DMD as well as trends in functional improvement earlier than expected.”